Narayana Hrudayalaya Limited reported earnings results for the second quarter and six months ended September 30, 2025. For the second quarter, the company reported sales was INR 16,437.9 million compared to INR 13,666.82 million a year ago. Revenue was INR 16,677.82 million compared to INR 13,901.95 million a year ago. Net income was INR 2,583.71 million compared to INR 1,986.33 million a year ago. Basic earnings per share from continuing operations was INR 12.71 compared to INR 9.8 a year ago. Diluted earnings per share from continuing operations was INR 12.71 compared to INR 9.8 a year ago. Basic earnings per share was INR 12.72 compared to INR 9.78 a year ago. Diluted earnings per share was INR 12.72 compared to INR 9.78 a year ago.
For the six months, sales was INR 31,510.59 million compared to INR 26,729.49 million a year ago. Revenue was INR 31,988.43 million compared to INR 27,198.52 million a year ago. Net income was INR 4,550.22 million compared to INR 4,000.08 million a year ago. Basic earnings per share from continuing operations was INR 22.36 compared to INR 19.68 a year ago. Diluted earnings per share from continuing operations was INR 22.36 compared to INR 19.68 a year ago. Basic earnings per share was INR 22.4 compared to INR 19.7 a year ago. Diluted earnings per share was INR 22.4 compared to INR 19.7 a year ago.
Narayana Hrudayalaya Limited is engaged in medical and healthcare services. The Company operates a network of multispecialty and super-specialty hospitals across multiple locations. Its operating segment is Medical and Healthcare Related Services. Its medical services include anesthesiology, audiology, breast oncology and oncoplastic surgery, clinical psychology, congenital adult heart disease, cardiac sciences, developmental and behavioral pediatrics, endocrinology and diabetology, gastrointestinal oncology, gynecologic oncology, hepatology and liver transplantation, interventional and endovascular radiology, medical gastroenterology, neuro rehabilitation, pediatric hematology oncology, speech and swallow rehabilitation, thoracic and vascular surgery, vascular and endovascular surgery, surgical gastroenterology, and surgical oncology, among others. It has a network of over 18 hospitals and three heart centers across India, along with an international presence in the Cayman Islands.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
